Bibliographies thématiques / Treatment of inflammatory disease

Littérature scientifique sur le sujet « Treatment of inflammatory disease »

Auteur : Grafiati
Publié le 10 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Treatment of inflammatory disease ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Treatment of inflammatory disease"

1

Fichna, Jakub. « Inflammatory bowel disease treatment ». Pharmacological Reports 68, no 4 (août 2016) : 787–88. http://dx.doi.org/10.1016/j.pharep.2016.05.008.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Leu, Sheng. « A Brief Review Chronic Inflammatory Autoimmune Disease : Multiple Sclerosis Pathogenesis and Treatment ». Neuroscience and Neurological Surgery 1, no 4 (22 novembre 2017) : 01–03. http://dx.doi.org/10.31579/2578-8868/016.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Yadollahpour, Ali. « A Brief Review Chronic Inflammatory Autoimmune Disease : Multiple Sclerosis Pathogenesis and Treatment ». Neuroscience and Neurological Surgery 1, no 4 (22 novembre 2017) : 01–03. http://dx.doi.org/10.31579/2578-8868/023.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

SANTOS, Rachael Miranda dos, Ana Teresa Pugas CARVALHO, Kelly dos Santos SILVA, Selma Petra Chaves SÁ, Aparecida Helena dos SANTOS et Millene Ramos SANDINHA. « INFLAMMATORY BOWEL DISEASE : OUTPATIENT TREATMENT PROFILE ». Arquivos de Gastroenterologia 54, no 2 (16 mars 2017) : 96–100. http://dx.doi.org/10.1590/s0004-2803.201700000-01.

Texte intégral
Résumé :
ABSTRACT BACKGROUND Crohn’s disease and ulcerative colitis are the two major forms of inflammatory bowel disease. The incidence and prevalence of both conditions have increased and are progressively increasing. These diseases are frequently recurrent and clinically highly severe. In Brazil, the lack of epidemiological data related to such diseases has left these patients in a vulnerable state and contributed to increased morbidity. OBJECTIVE To describe the profiles of patients with inflammatory bowel disease treated in an outpatient service in Brazil. METHODS This descriptive, exploratory, and retrospective documentary study with a quantitative approach was performed in an outpatient treatment service for inflammatory bowel disease, at a university polyclinic located in Rio de Janeiro, Brazil, from May to July 2016. The study included 556 patients and was approved by the research ethics committee of the institution (CAAE no. 55179316.6.0000.5259/2016). RESULTS The data showed a high prevalence of inflammatory bowel disease in white female patients. Crohn’s disease was diagnosed in more patients than was ulcerative colitis; the ileocolon was the most commonly affected location in patients with Crohn’s disease. The stenotic phenotype was prevalent in patients with Crohn’s disease. CONCLUSION The prevalence of the stenotic phenotype in Crohn’s disease in relation to others demonstrates the need for further investigations in this field of study in Brazil. In conclusion, the data showed that the epidemiologic profile of the study population is similar to that published in the national and international literature.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Eschenbach, D. « Treatment of Pelvic Inflammatory Disease ». Clinical Infectious Diseases 44, no 7 (1 avril 2007) : 961–63. http://dx.doi.org/10.1086/512200.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Quentin, R., et J. Lansac. « Pelvic inflammatory disease : medical treatment ». European Journal of Obstetrics & ; Gynecology and Reproductive Biology 92, no 2 (octobre 2000) : 189–92. http://dx.doi.org/10.1016/s0301-2115(99)00279-1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Watanabe, Mamoru, Daisuke Kubota, Masakazu Nagahori et Takanori Kanai. « Treatment of Inflammatory Immunologic Disease 1. Leukocytapheresis for Inflammatory Immunologic Disease (Tentative) ». Internal Medicine 46, no 16 (2007) : 1305–6. http://dx.doi.org/10.2169/internalmedicine.46.1911.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Teml, Alexander, Elke Schaeffeler, Klaus R. Herrlinger, Ulrich Klotz et Matthias Schwab. « Thiopurine Treatment in Inflammatory Bowel Disease ». Clinical Pharmacokinetics 46, no 3 (2007) : 187–208. http://dx.doi.org/10.2165/00003088-200746030-00001.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Gardiner, Sharon J., Evan J. Begg, Ashis Sau, Anthony Marinaki, Richard B. Gearry et Murray L. Barclay. « Thiopurine Treatment in??Inflammatory Bowel??Disease ». Clinical Pharmacokinetics 46, no 9 (2007) : 803–4. http://dx.doi.org/10.2165/00003088-200746090-00007.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Price, Ronald L. « Surgical Treatment of Ocular Inflammatory Disease ». Journal of Pediatric Ophthalmology & ; Strabismus 26, no 2 (mars 1989) : 75. http://dx.doi.org/10.3928/0191-3913-19890301-08.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Treatment of inflammatory disease"

1

Maiden, Laurence Peter. « Gastrointestinal inflammation : non steroidal anti-inflammatory drugs and inflammatory bowel disease ; novel evaluation and treatment of disease ». Thesis, King's College London (University of London), 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.497608.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Robinson, Richard John. « Osteoporosis in inflammatory bowel disease : aetiology, diagnosis and treatment ». Thesis, University of Leicester, 1998. http://hdl.handle.net/2381/29557.

Texte intégral
Résumé :
In 117 (male = 48) patients with Crohn's disease (CD) aged 20 to 65 years, bone mineral density (BMD) and biochemical markers of bone turnover were measured. Sex hormone status was assessed in men with CD. Hand skinfold thickness and calcaneal ultrasound were evaluated as screening tools for osteoporosis; and the effect of low impact exercise on BMD was prospectively studied. In patients with colitis, the effects of rectal steroids on bone turnover was investigated. The major determinants of BMD in CD were body weight, corticosteroids and male sex. Hypogonadism was an uncommon cause of flow BMD in men with CD. The bone resorption marker deoxypyridinoline was significantly increased in patients with CD compared to controls (10.97 (9.22) nMDPD/mMCreatinine vs 5.02 (1.03) mMDPH/mMCreatinine, difference in means-=5.95, 95% CI -9.6 to -2.3, p=0.00001) but bone formation markers were not significantly different. Hand skinfold thickness was significantly associated with BMD at the lumbar spine and femoral neck (r=0.43, 95% CI 0.27, 0.57 p<0.0001). However, the relation was inadequate to diagnose osteoporosis in an individual. Similarly, the sensitivity and specificity of calcaneal ultrasound were too low to recommend it as a screening tool for osteoporosis at the hip (sensitivity 66.7%, specificity 85.6%) or spine (sensitivity 75%, specificity 89%). Significant gains in BMD occurred at the trochanter of patients who fully complied with a 12 month exercise programme (+7.7% (8.2) vs +3.1% (5.83), difference in means=4.67%, 95% CI 0.86 to 8.48, p=0.02). Increases in BMD were significantly related to compliance with the exercises and were independent of other potential confounding variables. In patients with colitis, rectally administered corticosteroids had no significant effects on bone turnover. Bone resorption is increased in patients with CD who are at high risk of low BMD. Corticosteroids are an important aetiological factor and rectally administered steroids should be prescribed wherever possible. Low impact exercise could be an effective method of increasing BMD in some patients with CD.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Lindberg, Johan. « Transcriptional patterns in inflammatory disease ». Doctoral thesis, Stockholm : Bioteknologi, Kungliga Tekniska högskolan, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-9117.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Wolf, Stefan. « Novel Approaches in the Treatment of Virus- Induced Inflammatory Disease ». Thesis, Griffith University, 2016. http://hdl.handle.net/10072/366853.

Texte intégral
Résumé :
This PhD thesis combines four chapters on different fields of basic research and sets the focus on two circulating viruses of global concern, the orthomyxovirus influenza A virus (IAV) and the alphavirus Ross River virus (RRV). The first three chapters include swine influenza A virus (sIAV) surveillance for the detection and characterisation of IAV subtypes, an in vitro high throughput screening (HTS) on host micro RNAs (miRNAs) for the discovery of novel anti-IAV (H7N9) targets and their underlying mechanisms, and an approach to reduce disease pathogenesis in mice infected with H7N9 by targeting the pro-inflammatory factor CCL2. In a fourth chapter, drug repurposing with the interleukin-1 (IL-1) inhibitor anakinra was investigated to treat RRV-induced bone loss in mice. By combining these four chapters, a broad range of drug discovery is covered in this PhD thesis; Surveillance, HTS target discovery and the application of drug repurposing in animal models of viral diseases.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
Institute for Glycomics
Science, Environment, Engineering and Technology
Full Text
Styles APA, Harvard, Vancouver, ISO, etc.
5

Bailey, Mark Allan. « Synthesis and Analysis of Novel Anti-Inflammatory Conjugates for the Treatment of Inflammatory Bowel Disease ». Thesis, University of Brighton, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.485757.

Texte intégral
Résumé :
Current aminosalicylic acid (ASA) preparations are used to induce and control the remission of inflammatory bowel diseases (IBOs); however, only partial success has been achi~ved. Hence, in the absence of a satisfactor~ treatment or a cure, there is a need for the development of further therapeutic strategies to combat IBOs. The objective of this study was to explore new therapeutic avenues by developing novel conjugates of the active ASAs pharmacophore. These conjugates were designed to incorporate the ASA with other moieties which show therapeutically useful properties. This report includes the design, synthesis and characterisation of novel ASA and aliphatic amino acid (AA) conjugates with the antioxidant ethylenediaminetetraacetic acid (EOTA). Diglyceride and model polymeric delivery systems were also investigated, although, these two alternative areas were not highly successful. All the EOTA conjugates· described in this study are readily synthesised in two steps using standard methyl ester and amide-bond formation techniques. A wide range of biochemical properties were studied for the conjugates synthesised in this project. These studies determined the effectiveness of the conjugates in the combat against IBOs. These properties included metal ion chelation, reactive oxygen species (ROS) suppression, proteolytic and pH stabilities, as well as anti-cancer activity. Firstly, the chelation of labile transition metal ions has been shown to remove the ion's pro-oxidant activity. The removal of pro-oxidant activities by chelation could assist in the treatment of IBOs, which has been shown to be linked with oxidative stress. Secondly, due to a link between ROS and IBOs, the discovered ROS suppression would also be advantageous in the combat against IBOs. Thirdly, the gastrointestinal stability of these conjugates is favourable; as, reaching the disease site (Le. the colon and terminal ileum) intact would enable the conjugates to function as designed. And fourthly, due to a link between IBOs and cancer, ethylenediaminetetraacetic acid bis-(5-aminosalicylic acid methyl ester) was tested in the National Cancer Institute's 60 cancer cell-line.· The synthesised conjugates showed an ideal 1: 1 binding ratio with the transition metal ions Cu(lI) and Fe(III). ROS suppression was observed for all the synthesised compounds whe~ chelatcd to redox active transition metal ions. In the stability studies, it was found that the ASA conjuga.tes were· stable to proteolytic attack. This was in contrast to the AA conjugates, which were· readily degraded by protease. Additionally, all the studied conjugates showed excellent pH stabilities. And lastly; the 5-ASA-EDTA conjugate showed promising in vitro anti-cancer activity. This study reports novel anti-inflammatory conjugates, which show promising properties for use in the combat against IBOs. Results from this project have shown that the conjugates are able to chelate toxic, unbound transition metal ions, which in turn forms strong ROS suppressors. The work within this report has also shown excellent protease and pH stabilities of the ASA conjugates, which would enable them to travel through the upper gastrointestinal tract intact. Upon reaching the ~ite of disease, they would be able to either act as novel anti-inflammatory, chelating conjugates, or, as prodrugs which would then release the ASA moiety via bacterial reduction, The anti-cancer activity shown for one of the conjugates would also be beneficial in IBO treatment.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Mitchison, Harriet Caroline. « Primary biliary cirrhosis : studies in prognosis, early diagnosis, bone disease and treatment ». Thesis, University of Newcastle Upon Tyne, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.241281.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Smith, Melissa Ann. « Optimising the use of Azathioprine in the treatment of Inflammatory Bowel Disease ». Thesis, King's College London (University of London), 2016. https://kclpure.kcl.ac.uk/portal/en/theses/optimising-the-use-of-azathioprine-in-the-treatment-of-inflammatory-bowel-disease(c05015ac-a88a-4322-b457-200af7c11118).html.

Texte intégral
Résumé :
Azathioprine (AZA) and mercaptopurine (MP – also known as 6-mercaptopurine or 6MP) are the first line immunomodulatory treatments for inflammatory bowel disease (IBD) with proven efficacy for multiple clinical outcomes (fistula closure, steroid withdrawal, maintenance of remission etc.). They also have a wide application in the fields of rheumatology, dermatology, haematology and transplant medicine. However these drugs also cause toxicity and may be ineffective. Both of these outcomes can have serious consequences for the individual concerned. A proportion of toxicity caused by these drugs is explained by genetic polymorphism in the enzyme thiopurine methyltransferase (TPMT), however the majority of toxicity remains unexplained and as yet there is no satisfactory explanation for the variable efficacy of these drugs. In this thesis I explore the impact of genetic polymorphism in several novel candidate genes involved in thiopurine metabolism on the success of thiopurine treatment. Single nucleotide polymorphisms (SNPs) in xanthine oxidase/dehydrogenase (XDH) and the final enzymatic step which activates its essential cofactor (molybdenum cofactor sulfurase, MOCOS) are shown to protect against side effects to AZA therapy. Polymorphism in aldehyde oxidase (AOX) and multi-drug resistance protein 5 on the other hand, are shown to predict a lack of response to thiopurine treatment. Sequencing AOX validated the real-time PCR results and suggested that there were no other coding SNPs likely to be contributory. A pharmacogenetic index incorporating these new markers with established predictors of outcome on thiopurines is presented and the clinical utility of such an index discussed. Finally, clinical data supporting the optimisation of azathioprine therapy, both by the measurement of thioguanine metabolite profiles and through co-prescription of allopurinol are presented.
Styles APA, Harvard, Vancouver, ISO, etc.
8

SALA, EMANUELA. « MESENCHYMAL STEM CELLS : MECHANISMS INVOLVED IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE ». Doctoral thesis, Università degli Studi di Milano, 2013. http://hdl.handle.net/2434/218985.

Texte intégral
Résumé :
Background. Mesenchymal stem cells (MSC) based on their immune-modulatory and anti-inflammatory properties have been candidate as therapeutic treatment for several immune disease including inflammatory bowel disease (IBD). Although most of beneficial effects are explained by MSC engrafting at the site of tissue injury with modulation of inflammatory reactions, the mechanisms by which MSC exert their activities needed to be elucidated. Aim of this study was to investigate the mechanisms underlying the therapeutic efficacy of MSC in Dextran Sodium Sulphate (DSS) induced colitis. Methods. Colitis was induced in C57BL6 mice by 3% DSS treatment for 10 days. MSC were isolated from bone marrow of wild type (WT) and GFP-transgenic C57BL6 mice, cultured for 4 weeks and then sorted for Sca-1+, CD31-, cocktail lineage- surface markers. At day 5 of colitic induction the mice were treated intraperitoneally with a single injection of 3x106 GFP-MSC or with 5 daily injections of recombinant murine TNFα-stimulating gene protein 6 (TSG-6) (4 μg). Body weight and disease activity index (DAI) were monitored daily and the damage of murine colonic mucosa was evaluated by endoscopic and histological scores. To follow the migratory activity of the MSC, GFP-MSC were injected intraperitoneally in healthy or colitic mice at day 5 and their presence was assessed by flow cytometry after 24 and 48 hours in the colon and mesenteric lymph nodes. Levels of TSG-6, IL-6 and IFN-γ were measured in serum and in mucosal extracts by ELISA, while MMP activities were quantified by WB. Results. We found that one injected into the peritoneum MSC remain into the peritoneal cavity, where they aggregate along with macrophages and lymphocytes, generating organized structures. Only a small fraction (< 1%) of cells reached the inflamed colon. In vitro and in vivo assays have demonstrated that MSC secrete a multipotent anti-inflammatory protein TSG-6 able to reduce the damage to the colon. In fact, recombinant murine TSG-6 treatment improved survival rate and DSS-induced colitis by reducing markedly both systemic and mucosal levels of IL-6, IFN-γ, neutrophil infiltration, and MMP activities. Conclusions. Overall, these data indicate that the MSC gut-homing is not relevant for exerting their immunomodulatory effects, but MSC dampen the mucosal inflammatory response at distance by releasing a potent anti-inflammatory protein.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Liefferinckx, Claire. « Evaluation of disease severity in inflammatory bowel diseases : From predictive diagnostic gene markers to treatment optimization based on pharmacokinetics ». Doctoral thesis, Universite Libre de Bruxelles, 2019. https://dipot.ulb.ac.be/dspace/bitstream/2013/286479/3/table.docx.

Texte intégral
Résumé :
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory immune-mediated diseases of the gastrointestinal tract. Two-thirds of IBD patients will develop severe disease, with complications that will require frequent surgeries and hospital admissions, and will seriously impair their quality of life. The ultimate clinical challenge of precision medicine in IBD is to find predictive markers to anticipate the development of severe disease and to monitor treatment in these patients.In the first part of my PhD thesis, we have carried out several studies monitoring the biologics used in IBD patients with severe disease. We have evaluated the pharmacokinetics of the following biologics used in IBD patients: infliximab, vedolizumab, and ustekinumab. We have focused on measuring trough levels (TLs) (defined as the serum drug level measured just before the next drug administration) early on after initiating biologic treatment to predict patient outcomes, including long- term responses in patients treated with infliximab and vedolizumab. In addition, we are currently conducting a prospective multicentric study that aims to design a pharmacokinetic model of infliximab at induction in IBD patients (EudraCT: CT 2015- 004618-10) (End of study expected by December 2019 but interim analysis available in the present work). Moreover, we have reported on the efficacy of ustekinumab in a large national cohort of highly refractory CD patients and have also examined the benefit of early measurement of ustekinumab TLs in these patients. Finally, we have reported novel findings on the impact of different wash-out periods (defined as the time frame between the discontinuation of one biologic and the initiation of a second biologic on the pharmacokinetics of the second-line biologic). Altogether, over the past 3 years, our data suggest the importance of measuring TLs early on during induction to predict long-term response to biologics during maintenance therapyIn the second part of my PhD thesis, we have analysed the inter-variability of the immune response in healthy subjects. Inflammation is the obvious key driver and underlying mechanism of disease severity in IBD. Therefore, the magnitude of inflammation must help define the phenotype of mild to severe disease. Delineating the inter-variability of the immune response in a healthy cohort constitutes a fundamental step to uncovering the genetic factors underlying this variability. We have performed whole blood cell cultures in a highly selected population of more than 400 healthy subjects stimulated with several Toll-like receptor (TLR) agonists and a T-cell receptor (TCR) antagonist. We found that the magnitude of the immune response (the high- or low-cytokine producer phenotype) was independent of the cytokine measured and the TLR agonists used. Thus, a donor exhibits a specific immune (cytokine) response or “immunotype” across cytokines released and TLR stimulation. Importantly, the high- or low-cytokine producer phenotype was different and did not overlap between the TLR and TCR stimulation conditions. In other words, a donor who is ahigh-cytokine producer following TLR stimulation will not be a high-cytokine producer following TCR stimulation (or the inverse). Therefore, we have defined TLR- or TCR- related Immunotypes (IT) as “a grading classification of the magnitude of the cytokine immune response” with IT1, IT2, and IT3 as low, intermediate, and high immunotypes. This suggests that two independent TLR and TCR ITs (TLR IT1 and TCR IT3) can co-exist in the same subject. We are now currently evaluating the genetic markers underlying these ITs before validating them in large cohort of IBD patients with mild-to-moderate and severe disease.This PhD thesis provides some data suggesting that the assessment of the pharmacokinetics of biologics early on at the initiation of treatment could help predict how the patient will respond in the long run. In parallel, this PhD thesis provides some advances in the understanding of the inter-variability of the immune response, a fundamental step before the identification of potential genetic markers underlying the inter-variability of inflammation and, hence, the severity of disease in IBD.
Doctorat en Sciences biomédicales et pharmaceutiques (Médecine)
info:eu-repo/semantics/nonPublished
Styles APA, Harvard, Vancouver, ISO, etc.
10

Schmitz, Silke. « Investigations into the efficacy of probiotics in canine inflammatory bowel disease ». Thesis, Royal Veterinary College (University of London), 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.618324.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Livres sur le sujet "Treatment of inflammatory disease"

1

National Institute of Allergy and Infectious Diseases (U.S.), dir. Pelvic inflammatory disease. [Bethesda, Md : National Institute of Allergy and Infectious Diseases, 1992.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

1934-, Nozik Robert A., dir. Surgical treatment of ocular inflammatory disease. Philadelphia : Lippincott, 1988.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

L, Gitnick Gary, dir. Inflammatory bowel disease : Diagnosis and treatment. New York : Igaku-Shoin, 1991.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

L, Gitnick Gary, dir. Inflammatory bowel disease : Diagnosis and treatment. New York : Igaku-Shoin, 1991.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Cheifetz, Adam S., et Joseph D. Feuerstein, dir. Treatment of Inflammatory Bowel Disease with Biologics. Cham : Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-60276-9.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Torben, Lildholdt, et Mygind Niels, dir. Nasal polyposis : An inflammatory disease and its treatment. Copenhagen : Munksgaard, 1997.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Québec) Falk Symposium (66th 1992 Québec. Trends in inflammatory bowel disease therapy. Dordrecht : Kluwer Academic Publishers, 1993.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Falk Symposium (66th 1992 Quebec City, Québec). Trends in inflammatory bowel disease therapy. Dordrecht : Kluwer Academic Publishers, 1993.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

J, Huang John, et Gaudio Paul A, dir. Ocular inflammatory disease and uveitis manual : Diagnosis and treatment. Philadelphia : Wolters Kluwer/Lippincott Williams & Wilkins Health, 2010.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

N, Williams C., Canadian Association of Gastroenterology et Interfalk Canada Inc, dir. Trends in inflammatory bowel disease therapy. Dordrecht : Kluwer Academic Publishers, 1991.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Chapitres de livres sur le sujet "Treatment of inflammatory disease"

1

Sobrado, Carlos Walter, et Wilton Schmidt Cardozo. « Surgical Treatment in Crohn's Disease ». Dans Inflammatory Bowel Disease, 431–63. 2e éd. New York : River Publishers, 2022. http://dx.doi.org/10.1201/9781003338550-29.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Teixeira, Magaly Gemio. « Surgical Treatment in Ulcerative Colitis ». Dans Inflammatory Bowel Disease, 419–29. 2e éd. New York : River Publishers, 2022. http://dx.doi.org/10.1201/9781003338550-28.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Sweet, Richard L. « Treatment of Acute Pelvic Inflammatory Disease ». Dans Pelvic Inflammatory Disease, 76–93. New York, NY : Springer New York, 1997. http://dx.doi.org/10.1007/978-1-4612-0671-2_5.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Sobrado, Carlos Walter, et Wilton Schmidt Cardozo. « Treatment of Perianal Fistulizing Crohn's Disease ». Dans Inflammatory Bowel Disease, 465–89. 2e éd. New York : River Publishers, 2022. http://dx.doi.org/10.1201/9781003338550-30.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Blanchard, Edward B. « Inflammatory bowel disease. » Dans Irritable bowel syndrome : Psychosocial assessment and treatment., 133–38. Washington : American Psychological Association, 2001. http://dx.doi.org/10.1037/10393-012.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Hurst, Roger. « Innovations in the Surgical Treatment of Inflammatory Bowel Disease ». Dans Inflammatory Bowel Disease, 165–75. Totowa, NJ : Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60327-433-3_11.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Mattei, Peter. « Surgical Treatment of Ulcerative Colitis ». Dans Pediatric Inflammatory Bowel Disease, 519–31. Cham : Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-49215-5_42.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Mattei, Peter. « Surgical Treatment of Ulcerative Colitis ». Dans Pediatric Inflammatory Bowel Disease, 417–29. New York, NY : Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5061-0_38.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Mattei, Peter. « Surgical Treatment of Ulcerative Colitis ». Dans Pediatric Inflammatory Bowel Disease, 585–95. Cham : Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-14744-9_41.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Greiner, Kathrin H., et John V. Forrester. « Immunotherapy for ocular inflammatory disease ». Dans Treatment of Autoimmune Disorders, 49–58. Vienna : Springer Vienna, 2003. http://dx.doi.org/10.1007/978-3-7091-6016-9_6.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Treatment of inflammatory disease"

1

Afonso, L. Senra, M. Oro Fernández, C. Garay Sarría, H. Cristóbal Gutiérrez, MA Martín Vega, E. Martínez de Ilarduya Bolado, N. Lizama Gómez, JF Mayorga Pérez, A. Illaro Uranga et M. Valero Domínguez. « CP-202 Ustekinumab treatment in refractory inflammatory bowel disease ». Dans 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.200.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Hernández, R., A. Perez Gil, J. Uceda et JL Marenco de la Fuente. « P095 Inflammatory bowel disease, during anti IL 17 treatment ». Dans 39th European Workshop for Rheumatology Research, 28 February–2 March 2019, Lyon, France. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2018-ewrr2019.84.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

SPIE, Proceedings of. « Front Matter : Volume 10479 ». Dans Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases, sous la direction de Tianhong Dai. SPIE, 2018. http://dx.doi.org/10.1117/12.2315737.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Chang, Kwang Poo, Bala K. Kolli, Dennis K. P. Ng, Laura Manna, Robert L. Elliott, Raffaele Corso, X. P. Jiang et al. « Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides ». Dans Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases, sous la direction de Tianhong Dai. SPIE, 2018. http://dx.doi.org/10.1117/12.2281437.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Dai, Tianhong, et Ying Wang. « Antimicrobial blue light : a drug-free approach for inactivating pathogenic microbes ». Dans Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases, sous la direction de Tianhong Dai. SPIE, 2018. http://dx.doi.org/10.1117/12.2283019.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Welch, David, Henry M. Spotnitz, David J. Brenner, Gerhard Randers-Pehrson, Manuela Buonanno et Igor Shuryak. « Far-UVC light applications : sterilization of MRSA on a surface and inactivation of aerosolized influenza virus ». Dans Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases, sous la direction de Tianhong Dai. SPIE, 2018. http://dx.doi.org/10.1117/12.2309424.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Hamblin, Michael R., et Liyi Huang. « Potentiation by potassium iodide using TPPS4 for antimicrobial photodynamic inactivation ». Dans Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases, sous la direction de Tianhong Dai. SPIE, 2018. http://dx.doi.org/10.1117/12.2285246.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Weintraub, Eitan, Ben Sachs, Yana Reznick, Moshe Sinvani, Rachel Lubart, Ehud Banin, Yevgeny Beiderman et Zeev Zalevsky. « Usage of light for enhanced sensing and treating of inflammations and infections (Conference Presentation) ». Dans Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases, sous la direction de Tianhong Dai. SPIE, 2018. http://dx.doi.org/10.1117/12.2287083.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Zhao, Yuxia, Ying Gu, Shaona Zhou et Zhiyuan Sun. « A quaternary ammonium modified coumarin derivative for antimicrobial photodynamic therapy ». Dans Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases, sous la direction de Tianhong Dai. SPIE, 2018. http://dx.doi.org/10.1117/12.2287086.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

de Freitas, Laura M., Ana L. Blanco et Carla R. Fontana. « Antimicrobial photodynamic therapy proved not to induce bacterial resistance (Conference Presentation) ». Dans Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases, sous la direction de Tianhong Dai. SPIE, 2018. http://dx.doi.org/10.1117/12.2287268.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Treatment of inflammatory disease"

1

Velusamy, Yasothaa, Muhammad Hibatullah Romli, Putri Yubbu, Shankar Aissvarya et Karuppiah Thilakavathy. Safety And Efficacy of Pharmacological Approaches Available for Multisystem Inflammatory Syndrome in Children (Mis-C) : A Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, février 2022. http://dx.doi.org/10.37766/inplasy2022.2.0052.

Texte intégral
Résumé :
Review question / Objective: What are the evidence on safety and efficacy of pharmacological treatments used in MIS-C management? Condition being studied: Multisystem Inflammatory Syndrome in Children (MIS-C) - In early 2020, rare cases associated with SARS-CoV-2 were reported in children known as Multisystem Inflammatory Syndrome in Children (MIS-C) by the Centers for Disease Control and Prevention. This condition which is also known as Paediatric Inflammatory Multisystem Syndrome (PIMS) was initially presented as Kawasaki disease as it has similar symptoms. However, MIS-C was then defined as a new disease because of several differences in features. This emergence addresses the need for safe and efficient treatment approaches.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Garcia, Martin, et Pedro Tinedo. ADJUVANT EFFECT OF PROPOLIS TO PERIODONTAL THERAPY FOR THE TREATMENT OF PERIODONTAL DISEASE : A SYSTEMATIC REVIEW. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, mars 2022. http://dx.doi.org/10.37766/inplasy2022.3.0030.

Texte intégral
Résumé :
Review question / Objective: In patients with periodontal disease, what will be the scientific evidence on the adjuvant effect of Propolis to periodontal therapy for the treatment of periodontal disease? Condition being studied: Periodontal Disease or Periodontitis, an inflammatory disease that affects the supporting tissues that surround the tooth, which are currently being studied with natural products that would work as an adjuvant to periodontal therapy and obtain better results. Information sources: Three digital data sources were used, PUBMED, SCOPUS and EMBASE.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Grueso-Navarro, Elena, Leticia Rodríguez-Alcolado, Ángel Arias, Emilio J. Laserna-Mendieta et Alfredo J. Lucendo. Influence of HLA-DQA1*05 allele in the response to anti-TNFα drugs in inflammatory bowel diseases. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, février 2023. http://dx.doi.org/10.37766/inplasy2023.2.0076.

Texte intégral
Résumé :
Review question / Objective: Do patients with inflammatory bowel disease and treated with any anti-TNFα drug who had the HLA-DQA1*05 allele (in heterozygosis or homozygosis) have lower response or persistence to those drugs than patients without HLA-DQA1*05 allele? Condition being studied: Inflammatory bowel diseases (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition that may affect any part of the digestive tract (CD) or be limited to the colon (UC). While the specific aetiology of IBD remains unknown, it is believed to involve a complex impairment in the immunity of the gut mucosa due to a combination of several genetic and environmental factors, being the microbiota one of the latest that more attraction has received in recent years. Symptoms of IBD (such as abdominal pain, diarrhoea, fever, tiredness or rectal bleeding) may be either constant or alternate between periods of limited disease activity and flares with remarkable presence of symptoms. As IBD is associated with significant morbidity and disability, pharmacological treatment is required in most cases, especially in CD, aimed at reducing the inflammatory response and attenuating the activity of the immune system. In the moderate and severe forms of the disease, therapy is usually based on immunosuppressant and/or biological drugs. Among the latest, anti-TNFα drugs (infliximab or adalimumab) are normally chosen as the initial biological therapy.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Sun, Lina, Yanan Han, Hua Wang, Huanyu Liu, Shan Liu, Hongbin Yang, Xiaoxia Ren et Ying Fang. MicroRNAs as Potential Biomarkers for the Diagnosis of Inflammatory Bowel Disease : A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, février 2022. http://dx.doi.org/10.37766/inplasy2022.2.0027.

Texte intégral
Résumé :
Review question / Objective: The purpose of this systematic review was to systematically review the clinical studies regarding miRNAs as diagnostic biomarkers for inflammatory bowel disease and assess the overall diagnostic accuracy of miRNAs. Condition being studied: The symptoms of inflammatory bowel disease (IBD) are highly variable. The diagnosis of IBD must be made through medical history, physical, laboratory, radiologic, endoscopic, and histological examinations. However, these diagnostic techniques are not specific and sometimes even equivocal. Therefore, reliable biomarkers are urgently needed in the diagnosis of IBD. Several clinical and preclinical researches have shown that dysregulated microRNAs (miRNAs) play a crucial role in IBD development. miRNAs, as single-stranded noncoding RNAs that contain 22-24 nucleotides, can post-transcriptionally regulate gene expression by blocking mRNA translation or degrading target mRNAs. miRNAs are widely involved in physiological and pathological cellular processes, such as differentiation, proliferation and apoptosis. Besides, they are stable, noninvasive, and resistant to degradation by ribonucleases, making them valuable targets in the diagnosis, monitoring, prognosis, and treatment of diseases. To date, inconsistent results have been found about miRNA expression profiling in the patients with IBD. Moreover, the diagnostic accuracy of miRNAs for IBD has not been reported in any meta-analysis.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Parvova, Iva, Emil Hristov, Rasho Rashkov, Ilko Getov et Sava Ognianov. Safety of Biological Treatment in a Bulgarian Population of Patients with Inflammatory Joint Diseases : Retrospective Study of Adverse Drug Reactions. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, octobre 2019. http://dx.doi.org/10.7546/crabs.2019.10.14.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Liu, Miao, Hongan Wang, Jing Lu, Zhiyue Zhu, Chaoqun Song, Ye Tian, Xinzhi Chen et al. Vitamin D supplementation in the treatment of Myasthenia Gravis A protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septembre 2022. http://dx.doi.org/10.37766/inplasy2022.9.0129.

Texte intégral
Résumé :
Review question / Objective: The patients should meet the internationally recognized diagnostic criteria for myasthenia gravis and be definitely diagnosed as myasthenia gravis, excluding MG patients caused by congenital, drug and other factors, as well as patients with serious primary diseases, autoimmune diseases or mental diseases. Patients are not restricted by race, region, gender, age, background, course of disease and other factors. We will focus on trials using vitamin D as an intervention at any dose and in any regimen (eg daily/weekly/monthly intake). The control group was routinely given western medicine, including cholinesterase inhibitors, glucocorticoids, immunosuppressants, alone or in combination, or placebo. The intervention group was treated with vitamin D on the basis of western medicine treatment in the control group. The specific dosage form and dose were not limited, and the shortest course of treatment should be 4 weeks. Main outcome measures: (1) Quantitative score of myasthenia gravis (QMG); (2) Recurrence rate; (3) Effective. Secondary outcome measures: (1) The level of serum acetylcholine receptor antibody (AchRab); (2) The levels of inflammatory factors such as IL-6 and IL-10; (3) Clinical absolute score; (4) TCM syndrome score scale; (5) Quality of life score (QOL); (6) Incidence rate of adverse events. All randomized controlled trials (RCT) literatures from the establishment to September 2022 were retrieved and classified.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Ma, He, Jifu Zhao et Zhilei Wang. Efficacy and safety of HuaYu TongFu Method combined with acupuncture in the treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease：A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septembre 2022. http://dx.doi.org/10.37766/inplasy2022.9.0114.

Texte intégral
Résumé :
Review question / Objective: This study is the protocol for a systematic review to evaluate the efficacy and safety of HuaYu TongFu Method combined with acupuncture in the treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. we conducted a systematic review and meta-analysis of published randomized clinical trials (RCTs) of such combined therapy in the treatment of AECOPD, It provides a reliable scientific basis for clinicians to use this approach to treat AECOPD. Condition being studied: Chronic obstructive pulmonary disease is the third leading cause of death worldwide. AECOPD is the most common cause of hospitalization and death in patients with COPD. As lung function deteriorates and the disease progresses, the risk of alveolar hypoxia and consequent hypoxemia increases. Inflammation plays an important role in the progression of AECOPD. Modern medicine mainly treats AECPD by anti-inflammatory, relief of airway spasm, glucocorticoids, inhalants and other methods. Long-term application can easily lead to bacterial flora imbalance and drug resistance in patients. Comparatively, traditional Chinese medicine and acupuncture therapy are safe and effective.To assess the therapeutic efficacy and safety of HuaYu TongFu Method combined with acupuncture in AECOPD, we created a protocol for a systematic review to inform future clinical applications.
Styles APA, Harvard, Vancouver, ISO, etc.
8

LI, Peng, et Junjun Liu. Effect of statin therapy on moderate-to-severe depression : an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, mars 2022. http://dx.doi.org/10.37766/inplasy2022.3.0016.

Texte intégral
Résumé :
Review question / Objective: We aim to assess the antidepressant effects of statin therapy among patients complicated with moderate to severe depression. Condition being studied: Depression is one of the major causes of disability worldwide, and major depressive disorders (MDD) contribute to a significant heavy disease burden, which is expected to be second by 2050, only to heart disease. Despite great improvement in therapy, the treatment efficacy remains low. Therefore, alternative therapies have been intensely investigated. A substantial body of researches have suggested that inflammation is one of the operative pathways between MDD and increased risk of somatic comorbidities, and some specific depressive symptoms. Depression occurs in most patients with cardiac and cerebrovascular disease due to the long-term effects, and depression increases the risk of cardiovascular disease in the population as a whole and in patients with coronary artery disease or stroke. Several observational studies have demonstrated reduced rates of depression among patients taking statins, which may be related to its anti-inflammatory effect. However, whether statin improves the depressive symptoms and its associated mechanism is still mixed. Furthermore, there is little evidence about statin treatment effect in those with moderate to severe depression. In addition, whether the effect of statin treatment on depressive symptom changes with time or is affected by baseline depression severity or percentage change of lipid levels has not been explored in previous studies.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Schwartz, Bertha, Vaclav Vetvicka, Ofer Danai et Yitzhak Hadar. Increasing the value of mushrooms as functional foods : induction of alpha and beta glucan content via novel cultivation methods. United States Department of Agriculture, janvier 2015. http://dx.doi.org/10.32747/2015.7600033.bard.

Texte intégral
Résumé :
During the granting period, we performed the following projects: Firstly, we differentially measured glucan content in several pleurotus mushroom strains. Mushroom polysaccharides are edible polymers that have numerous reported biological functions; the most common effects are attributed to β-glucans. In recent years, it became apparent that the less abundant α-glucans also possess potent effects in various health conditions. In our first study, we explored several Pleurotus species for their total, β and α-glucan content. Pleurotuseryngii was found to have the highest total glucan concentrations and the highest α-glucans proportion. We also found that the stalks (stipe) of the fruit body contained higher glucan content then the caps (pileus). Since mushrooms respond markedly to changes in environmental and growth conditions, we developed cultivation methods aiming to increase the levels of α and β-glucans. Using olive mill solid waste (OMSW) from three-phase olive mills in the cultivation substrate. We were able to enrich the levels mainly of α-glucans. Maximal total glucan concentrations were enhanced up to twice when the growth substrate contained 80% of OMSW compared to no OMSW. Taking together this study demonstrate that Pleurotuseryngii can serve as a potential rich source of glucans for nutritional and medicinal applications and that glucan content in mushroom fruiting bodies can be further enriched by applying OMSW into the cultivation substrate. We then compared the immune-modulating activity of glucans extracted from P. ostreatus and P. eryngii on phagocytosis of peripheral blood neutrophils, and superoxide release from HL-60 cells. The results suggest that the anti-inflammatory properties of these glucans are partially mediated through modulation of neutrophileffector functions (P. eryngiiwas more effective). Additionally, both glucans dose-dependently competed for the anti-Dectin-1 and anti-CR3 antibody binding. We then tested the putative anti-inflammatory effects of the extracted glucans in inflammatory bowel disease (IBD) using the dextran sulfate sodium (DSS)–induced model in mice. The clinical symptoms of IBD were efficiently relieved by the treatment with two different doses of the glucan from both fungi. Glucan fractions, from either P. ostreatus or P. eryngii, markedly prevented TNF-α mediated inflammation in the DSS–induced inflamed intestine. These results suggest that there are variations in glucan preparations from different fungi in their anti-inflammatory ability. In our next study, we tested the effect of glucans on lipopolysaccharide (LPS)-induced production of TNF-α. We demonstrated that glucan extracts are more effective than mill mushroom preparations. Additionally, the effectiveness of stalk-derived glucans were slightly more pronounced than of caps. Cap and stalk glucans from mill or isolated glucan competed dose-dependently with anti-Dectin-and anti-CR-3 antibodies, indicating that they contain β-glucans recognized by these receptors. Using the dextran sulfate sodium (DSS)-inflammatory bowel disease mice model, intestinal inflammatory response to the mill preparations was measured and compared to extracted glucan fractions from caps and stalks. We found that mill and glucan extracts were very effective in downregulatingIFN-γ and MIP-2 levels and that stalk-derived preparations were more effective than from caps. The tested glucans were equally effective in regulating the number of CD14/CD16 monocytes and upregulating the levels of fecal-released IgA to almost normal levels. In conclusion, the most effective glucans in ameliorating some IBD-inflammatory associated symptoms induced by DSS treatment in mice were glucan extracts prepared from the stalk of P. eryngii. These spatial distinctions may be helpful in selecting more effective specific anti-inflammatory mushrooms-derived glucans. We additionally tested the effect of glucans on lipopolysaccharide-induced production of TNF-α, which demonstrated stalk-derived glucans were more effective than of caps-derived glucans. Isolated glucans competed with anti-Dectin-1 and anti-CR3 antibodies, indicating that they contain β-glucans recognized by these receptors. In conclusion, the most effective glucans in ameliorating IBD-associated symptoms induced by DSS treatment in mice were glucan extracts prepared from the stalk of P. eryngii grown at higher concentrations of OMSW. We conclude that these stress-induced growing conditions may be helpful in selecting more effective glucans derived from edible mushrooms. Based on the findings that we could enhance glucan content in Pleurotuseryngii following cultivation of the mushrooms on a substrate containing different concentrations of olive mill solid waste (OMSW) and that these changes are directly related to the content of OMSW in the growing substrate we tested the extracted glucans in several models. Using dextran sulfate sodium (DSS)–inflammatory bowel disease (IBD) mice model, we measured the colonic inflammatory response to the different glucan preparations. We found that the histology damaging score (HDS) resulting from DSS treatment reach a value of 11.8 ± 2.3 were efficiently downregulated by treatment with the fungal extracted glucans, glucans extracted from stalks cultivated at 20% OMSWdownregulated to a HDS value of 6.4 ± 0.5 and at 80% OMSW showed the strongest effects (5.5 ± 0.6). Similar downregulatory effects were obtained for expression of various intestinal cytokines. All tested glucans were equally effective in regulating the number of CD14/CD16 monocytes from 18.2 ± 2.7 % for DSS to 6.4 ± 2.0 for DSS +glucans extracted from stalks cultivated at 50% OMSW. We finally tested glucans extracted from Pleurotuseryngii grown on a substrate containing increasing concentrations of olive mill solid waste (OMSW) contain greater glucan concentrations as a function of OMSW content. Treatment of rat Intestinal epithelial cells (IEC-6) transiently transfected with Nf-κB fused to luciferase demonstrated that glucans extracted from P. eryngii stalks grown on 80% OMSWdownregulatedTNF-α activation. Glucans from mushrooms grown on 80% OMSW exerted the most significant reducing activity of nitric oxide production in lipopolysaccharide (LPS) treated J774A.1 murine macrophages. The isolated glucans were tested in vivo using the Dextran Sodium Sulfate (DSS) induced colitis in C57Bl/6 mice and found to reduce the histology damaging score resulting from DSS treatment. Expression of various intestinal cytokines were efficiently downregulated by treatment with the fungal extracted glucans. We conclude that the stress-induced growing conditions exerted by OMSW induces production of more effective anti-inflammatory glucans in P. eryngii stalks.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Albuquerque, Nila, Franklin Regis et Lucas Machado. Analysis of effectiveness, costs, quality of life, adherence and safety of the use of adalimumab in adults diagnosed with moderate to severe hidradenitis suppurativa : systematic review protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, octobre 2021. http://dx.doi.org/10.37766/inplasy2021.10.0010.

Texte intégral
Résumé :
Review question / Objective: What evidence is available in longitudinal studies on the use of adalimumab for the treatment of moderate to severe hidradenitis suppurativa in adults with a diagnosis of moderate to severe hidradenitis suppurativa in which systemic antibiotic therapy has been shown to be ineffective and/or in situations where they present intolerance or contraindication to systemic antibiotics, compared to the application of usual care without the use of adalimumab, regarding the reduction in the total count of abscesses and nodules, decreased sensation of pain, therapeutic adherence, increased levels of self-esteem and quality of life, improvement in inflammatory nodules, abscesses and fistulas costs and expenses associated with the treatment of the disease? Condition being studied: Moderate to severe hidradenitis suppurativa.
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Treatment of inflammatory disease » pour d’autres types de sources :
Articles de revues Thèses Livres
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie